Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 9/20 | 0.41 |
| ▸ | RXRB | P28702 | 8/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.41 |
| ▸ | RXRG | P48443 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722014 | 0.81 | RXRA (0.51) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL3405682 | 0.80 | RXRA (0.41) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL8554241 | 0.75 | PRKCA (0.36) | ALDH1A1POLBMAPT | |
| SCHEMBL1749434 | 0.73 | ALDH1A1 (0.53) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL4741957 | 0.73 | ALDH1A1 (0.44) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL12722405 | 0.72 | MAPT (0.42) | ALDH1A1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL13244605 | 0.71 | RXRA (0.42) | RXRARXRBNR4A2RXRGALDH1A1 | |
| SCHEMBL2720529 | 0.71 | PPARA (0.40) | RXRARXRB | |
| SCHEMBL13384898 | 0.70 | NR1H4 (0.51) | RXRARXRBNR4A2NPC1RAB9A | |
| SCHEMBL11938508 | 0.70 | SMN1; SMN2 (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-2257315-B1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3385253-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Lantheus Medical Imaging, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20160361448-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9408927-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9161997-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2015-10-20 | — | — | US | disclosed |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | TBXAS1 707/4885RXRA 3678/4885RXRB 3526/4885 |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | FABP7, MKI67, SLC5A7 | TBXAS1 699/4885RXRA 3344/4885RXRB 3216/4885 |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | MCOLN1, CNR1, SLC5A7 | TBXAS1 707/4885RXRA 3678/4885RXRB 3526/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-20160361448-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | TBXAS1 707/4885RXRA 3678/4885RXRB 3526/4885 |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | TBXAS1 325/4885RXRA 3869/4885RXRB 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.